Ceapro Inc V.CZO

Boehringer Ingelheim

[prophetoffactz]

Dr. Kjetil Ask has a paper that was accepted October 13, 2022. It was on the blockbuster drug nintedanib which has been used with PGX. The drug is owned by Boehringer Ingelheim and a long list of scientists from that company co-wrote the paper as highlighted below. Dr. Kjetil Ask keeps very good company when it comes to that drug. The conclusion of the paper: "Our study demonstrates the one of nintedanib's anti-fibrotic mechanisms is to increase IL-4 signaling in macrophages through inhibition of CSF1 receptor resulting in promotion of tissue repair phenotypes."

Anti-Fibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4-associated Tissue Repair Macrophages

 

 

Carolin K Watson , Daniela Schloesser , Katrin Fundel-Clemens , Carmen Lerner , Svenja Gabler , Praveen Baskaran , Christian T Wohnhaas , Stefanie Dichtl , Heinrich J Huber , Kjetil Ask , Florian Gantner , Show All...

-Author Information

• Carolin K Watson Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Immunology + Respiratory , Biberach, Germany
• Daniela Schloesser Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Katrin Fundel-Clemens Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Global Computational Biology, Biberach, Germany
• Carmen Lerner Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Svenja Gabler Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Praveen Baskaran Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Christian T Wohnhaas Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Stefanie Dichtl Max-Planck-Institute of Biochemistry, Martinsried, Bayern, Germany
• Heinrich J Huber Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Kjetil Ask McMaster University, Medicine, HAMILTON, Ontario, Canada
• Florian Gantner Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
• Coralie Viollet Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Matthew J Thomas Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Immunology & Respiratory Diseases Research, Biberach, Germany
• Fidel Ramirez Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Peter J. Murray Max-Planck-Institute of Biochemistry, Martinsried, Bayern, Germany
• Karim C El Kasmi Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany

Anti-Fibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4-associated Tissue Repair Macrophages | American Journal of Respiratory Cell and Molecular Biology | Articles in Press (atsjournals.org)

[Ciao]

Great find. Looking at the studies below, does it leave in vivo studies with mice and PGX Y-BG as a carrier for nintedanib to be conducted. If these pre-clinical mouse studies are successful, it seems possible that Boehringer Ingelheim would be a potential partner with Ceapro to conduct phase 1 clinical studies. The August NR expanding the work between Ceapro and McMaster makes all the sense now

[prophetoffactz]

"the potential to get a pharma partner for phase 1 human trials could be on the horizon." Gilles said in one of the presentations that they already know who they wanted to conduct a Phase I. Pending preclinical results Phase I trial design for fibrosis has been expected this year. I wonder if COVID provides a chance to do an accelerated trial in COVID patients too. CZO may be able to

[Ciao]

With product from all 8 suppliers below, the PGX process was able to produce an identical end product that met spec. This gives CZO a lot of lattitude with suppliers, supply input risk is greatly diminished.

[prophetoffactz]

"Several commercially available formulations of spray-dried YBG were further PGX processed and tested following the installation of a new piece of equipment. Promising results obtained showing that this new unit should enable the production of uniform particle sizes nearly independent of suppliers." new release CZO tested "several" suppliers and of that PGX was "nearly

[fossi_2002]

Boehringer Ingelheim is a subsidiary of Roche - and Ronnie Miller was CEO of Roche Canada for 22 years - does that come full circle? At least it could be helpful! Great information that Proph and Ciao keep giving us. The market is drying up and the chart looks very good.

[prophetoffactz]

Boehringer Ingelheim isn't a subsidiary of Roche. It is the largest private pharma company in the world and one of the world's top 20 pharma companies.

[fossi_2002]

Proph - that is correct. We have Boehringer Mannheim, which was acquired by Roche, and we have Boehringer Ingelheim, which is a private company.

[Ciao]

Fossi, thanks for joining in the conversation here. Some of us are truly excited about the prospects for the company. The work by Dr.Ask with BI highlighted by Proph helps us understand Ceapros direction for the pre clinical studies and strong candidates for potential partners. Now we are eagerly awaiting some study results.

[Hopeforthebest]

hey fossi, is that the same ronnie millerwho has yet to update his professional page on Linkendin, the same guy who has yet to accumalate any CZO stocks using his own money.How is he going to be help when he has shown that he is will to collect money but unwilling to promatoe Czo or put his money in the company?

[prophetoffactz]

CZO's stock is up 72.4% since Ronnie Miller joined the company and Hopeforthebest is still complaining about Canadian pharma icon Ronnie Miller. He's also complained about the volume all the way up. 

[Hopeforthebest]

used prophylatic you really are a waste of water, by the way how many share traded today, just over a 1000. Was that roonie's doing or did gagnon help. The fact remains roonie is so proud of joining CZO that he neglects to promote Czo when receiving awards or telling the professional world. That says alot. 1026 shares today, unfortunately those volumes are the norm not an anomaly

[prophetoffactz]

"If these pre-clinical mouse studies are successful, it seems possible that Boehringer Ingelheim would be a potential partner with Ceapro to conduct phase 1 clinical studies." PGX-YBG could be a stand-alone. Nintedanib's(OFEV) net sales in 2021 were 2.491 billion EUROS. Sales were up 22.2% vs. the previous year.